| 17. | INVESTMENTS |
| UNITED STATES DOLLAR | ||||||||
| 2017 | 2016 | |||||||
|
Listed |
||||||||
|
Cost |
143.0 | 62.9 | ||||||
|
Less: Accumulated impairments |
(45.5 | ) | (45.0 | ) | ||||
|
Net unrealised loss on revaluation |
(8.1 | ) | (7.4 | ) | ||||
|
Translation adjustment |
9.6 | — | ||||||
|
|
|
|
|
|||||
|
Carrying value |
99.0 | 10.5 | ||||||
|
|
|
|
|
|||||
|
Market value |
99.0 | 10.5 | ||||||
|
|
|
|
|
|||||
|
Unlisted |
||||||||
|
Carrying value at cost |
0.1 | 3.3 | ||||||
|
|
|
|
|
|||||
|
Derivative instruments |
||||||||
|
Warrants2 |
5.5 | 5.9 | ||||||
|
|
|
|
|
|||||
|
Total investments1 |
104.6 | 19.7 | ||||||
|
|
|
|
|
|||||
| 1 | All listed investments are classified as available for sale. Refer note 42 for details of major investments. |
| 2 | Consists of 10.0 million common share purchase warrants of Maverix. Refer note 15.1 for further details. |